abrdn World Healthcare Fund Q1 2025 Commentary
2025-06-03 08:20:00 ET
Summary
- The equity portion of the Fund rose (gross of fees) but underperformed its benchmark over the quarter.
- The top three detractors over the quarter were Novo Nordisk, uniQure and Teva Pharmaceutical Industries.
- The top three positive contributors were Roche Holding, AbbVie and AstraZeneca.
Fund performance
Read the full article on Seeking Alpha
For further details see:
abrdn World Healthcare Fund Q1 2025 CommentaryNASDAQ: AFSC
AFSC Trading
-3.1% G/L:
$31.27 Last:
7,264 Volume:
$31.415 Open:



